Cargando…

Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells

Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shujing, Wang, Xianyun, Li, Jing, Zhang, Jun, Zhang, Fan, Hu, Jie, Qi, Yixin, Yan, Baoyong, Li, Quanhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886089/
https://www.ncbi.nlm.nih.gov/pubmed/27293445
http://dx.doi.org/10.1155/2016/5896061
_version_ 1782434581611282432
author Li, Shujing
Wang, Xianyun
Li, Jing
Zhang, Jun
Zhang, Fan
Hu, Jie
Qi, Yixin
Yan, Baoyong
Li, Quanhai
author_facet Li, Shujing
Wang, Xianyun
Li, Jing
Zhang, Jun
Zhang, Fan
Hu, Jie
Qi, Yixin
Yan, Baoyong
Li, Quanhai
author_sort Li, Shujing
collection PubMed
description Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.
format Online
Article
Text
id pubmed-4886089
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48860892016-06-12 Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells Li, Shujing Wang, Xianyun Li, Jing Zhang, Jun Zhang, Fan Hu, Jie Qi, Yixin Yan, Baoyong Li, Quanhai Stem Cells Int Review Article Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases. Hindawi Publishing Corporation 2016 2016-05-17 /pmc/articles/PMC4886089/ /pubmed/27293445 http://dx.doi.org/10.1155/2016/5896061 Text en Copyright © 2016 Shujing Li et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Li, Shujing
Wang, Xianyun
Li, Jing
Zhang, Jun
Zhang, Fan
Hu, Jie
Qi, Yixin
Yan, Baoyong
Li, Quanhai
Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title_full Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title_fullStr Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title_full_unstemmed Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title_short Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells
title_sort advances in the treatment of ischemic diseases by mesenchymal stem cells
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886089/
https://www.ncbi.nlm.nih.gov/pubmed/27293445
http://dx.doi.org/10.1155/2016/5896061
work_keys_str_mv AT lishujing advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT wangxianyun advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT lijing advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT zhangjun advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT zhangfan advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT hujie advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT qiyixin advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT yanbaoyong advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells
AT liquanhai advancesinthetreatmentofischemicdiseasesbymesenchymalstemcells